dipyridamole has been researched along with Bone Marrow Diseases in 3 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Bone Marrow Diseases: Diseases involving the BONE MARROW.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 9.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 5.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "7 mg/kg/d of dipyridamole, we examined the relationships between 5FUra dose and steady-state plasma concentration (Css) and the percentage reduction in WBCs, as well as the percentage frequency of stomatitis." | 3.68 | Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. ( Egorin, MJ; Forrest, A; Remick, S; Trump, DL; Tutsch, KD; Willson, JK, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budd, GT | 1 |
| Herzog, P | 1 |
| Bukowski, RM | 1 |
| Pospísil, M | 1 |
| Hofer, M | 1 |
| Vacek, A | 1 |
| Netíková, J | 1 |
| Holá, J | 1 |
| Znojil, V | 1 |
| Weiterová, L | 1 |
| Trump, DL | 1 |
| Egorin, MJ | 1 |
| Forrest, A | 1 |
| Willson, JK | 1 |
| Remick, S | 1 |
| Tutsch, KD | 1 |
1 trial available for dipyridamole and Bone Marrow Diseases
| Article | Year |
|---|---|
Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; | 1994 |
2 other studies available for dipyridamole and Bone Marrow Diseases
| Article | Year |
|---|---|
Drugs elevating extracellular adenosine enhance cell cycling of hematopoietic progenitor cells as inferred from the cytotoxic effects of 5-fluorouracil.
Topics: Adenosine; Adenosine Monophosphate; Animals; Antimetabolites, Antineoplastic; Bone Marrow Diseases; | 2001 |
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.
Topics: Bone Marrow Diseases; Dipyridamole; Dose-Response Relationship, Drug; Drug Interactions; Fluorouraci | 1991 |